▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1448 by analyst upside · 2026-11-13
INSM
Insmed Incorporated
Healthcare · Market Cap $26B · P/E 0x
ANALYST PRICE TARGET
+64.5%
implied upside to consensus target
Current Price $118.07
Consensus Target $194.18
Bull Target $243.0
Bear Target $158.0
Analysts Covering 22
ANALYST CONSENSUS - BUY
Strong Buy
5
Buy
16
Hold
1
Sell
0
52-Week Low $90.39
52-Week High $212.75
YTD Return -33.3%
FUNDAMENTALS
Market Cap $26B
P/E Ratio (TTM) N/A
Forward P/E 179.4x
EPS (TTM) $-2.81
PEG Ratio 1.09
Dividend Yield N/A
Revenue (TTM) $1.5B
Profit Margin -39.9%
52-WEEK RANGE
52-Week Low $90.39
52-Week High $212.75
Current Price $118.07
Bear Target $158.0
Bull Target $243.0
● Now $118.07 ● Target $194.18
TRADING DATA
Avg Volume 2.8M
YTD Return -33.3%
Analyst Count 22
Consensus Buy
Upside to Target +64.5%
Last Updated 2026-11-13

ANALYST SUMMARY

Insmed Incorporated (INSM) is currently trading at $118.07 with a Wall Street consensus price target of $194.18, implying potential upside of 64.5% over the next 12 months. 22 analysts currently cover INSM, with a consensus rating of Buy - 95% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $243.0, while the most cautious has a target of $158.0.

INSM operates in the Healthcare sector with a market capitalisation of $26B. The stock is down 33.3% year-to-date and is currently trading near the lower end of its 52-week range of $90.39 – $212.75.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for INSM, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Guggenheim - Reiterated
Buy → Buy 2026-11-02 62% win rate (8 calls)
Morgan Stanley - Reiterated
Overweight → Overweight 2026-10-21 Building track record
Wolfe Research ↓ Downgrade
Outperform → Peer Perform 2026-10-12 Building track record
HC Wainwright & Co. reit
Buy → Buy 2026-10-12 31% win rate (48 calls)
Barclays - Reiterated
Overweight → Overweight 2026-09-30 Building track record
Roth Capital reit
Buy → Buy 2026-09-15 Building track record
JP Morgan - Reiterated
Overweight → Overweight 2026-08-10 43% win rate (7 calls)
Truist Securities reit
Buy → Buy 2026-08-10 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
62
out of 100
Coverage depth
24/30
Consensus clarity
16/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →